FierceBiotech ٢ يونيو ٢٠٢٦ ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
FierceBiotech ٢ يونيو ٢٠٢٦ ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
FierceBiotech ٢ يونيو ٢٠٢٦ MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
FierceBiotech ٢ يونيو ٢٠٢٦ Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
FierceBiotech ٢ يونيو ٢٠٢٦ ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data
FierceBiotech ١ يونيو ٢٠٢٦ ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
FierceBiotech ١ يونيو ٢٠٢٦ Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
FierceBiotech ١ يونيو ٢٠٢٦ Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
FierceBiotech ١ يونيو ٢٠٢٦ Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
FierceBiotech ١ يونيو ٢٠٢٦ Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear
FierceBiotech ١ يونيو ٢٠٢٦ Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome
FierceBiotech ٣١ مايو ٢٠٢٦ ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
FierceBiotech ٣١ مايو ٢٠٢٦ ASCO: Revolution Medicines confident in RAS leadership as rivals square up